Akebia Therapeutics Inc (AKBA) Stock AnalysisAKBAAkebia Therapeutics Inc

Akebia Therapeutics, Inc. is a fully integrated biopharmaceutical company with two commercial products for patients impacted by kidney disease. The Company's portfolio includes Vafseo and Auryxia. Vafseo is an orally administered medicine, approved by the United States Food and Drug Administration (FDA), for the treatment of anemia due to chronic kidney disease (CKD) in adult patients on dialysis for at least three months. Auryxia (ferric citrate) is an orally administered medicine approved and marketed in the United States for two indications: the control of serum phosphorus levels in adult patients with dialysis dependent chronic kidney disease (DD-CKD), and the treatment of iron deficiency anemia (IDA) in adult patients with non-dialysis-dependent chronic kidney disease (NDD-CKD). The Company's development pipeline includes mid-stage rare kidney disease pipeline assets (praliciguat and AKB-097) and early-stage pipeline assets (AKB-9090 and AKB-10108), which are HIF molecules. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Given the current price of $0.5669 and the RSI of 10.705, which indicates the stock is oversold, there may be a potential for a rebound. However, the significant 82.12% decline over the past year and the negative net income of -$8.9 million in Q2 2026 raise serious concerns. The downgrade by Leerink to a $1 target suggests that the market is cautious about Akebia's future performance, making it a sell for now.

7 analysts cover AKBA: 6 rate it Buy, 1 Hold and 0 Sell. The average price target is 5.00.